Retreatment Strategies for Patients Failing First-Line Therapy
Source: Advanced Topics in Hepatitis C Management: Tools for Nurse Practitioners and Physician Assistants

Module

HoChong Gilles, RN, MS, FNP, reviews clinical management options for patients with chronic HCV infection who fail interferon-based therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify causes of nonresponse and relapse to hepatitis C virus (HCV) therapy
  • Describe definitions of response during HCV therapy and key time points for monitoring response to treatment
  • Discuss diagnosis and management of common adverse effects of HCV therapy and strategies for monitoring patient adherence
  • Recall strategies for selecting optimal treatment for patients based on their baseline factors and previous course of therapy

Topics covered include:

  • Introduction
  • Treatment Response Patterns
  • Factors Contributing to Treatment Failure
  • Comorbidities as Predictors of Nonresponse
  • Other Factors Associated With Nonresponse
  • Assessing Factors Related to Nonresponse Before Retreatment
  • Retreatment Options in Nonresponders and Relapsers
  • Summary: Implications for Clinical Practice
 

Program Directors

  • Michael W. Fried
    MD

Faculty

  • HoChong Gilles
    RN, MS, FNP

Credit Information

  • Release Date:
    June 28, 2007
  • Expiration Date:
    June 27, 2008
  • Physicians:
    maximum of 1.5 AMA PRA Category 1 Credits
  • Registered Nurses:
    1.5 Nursing contact hours
  • Physician Assistants:
    maximum of 1.5 hours of AAPA Category I (Preapproved) credits
  • My Take on the Guidance From AASLD/IDSA for Managing Treatment-Experienced Patients With Genotype 1 HCV Infection and Cirrhosis

    Nezam H. Afdhal MD, FRCPI - 11/4/2014    6 comments / Last Comment: 12/9/2014
    New regimens are becoming available for genotype 1 HCV infection that offer more data and apparently better efficacy than previously recommended regimens in patients with cirrhosis who have experienced previous treatment failure.
  • All-Oral Therapy for HCV: Rewriting the Course of the Disease

    Nancy Reau MD - 11/3/2014    5 comments / Last Comment: 12/9/2014
    All-oral HCV therapies are erasing the importance of traditional obstacles to cure
  • My Take on the Guidance From AASLD/IDSA for Treating PI-Experienced Patients With Genotype 1 HCV Infection

    Norah Terrault MD, MPH - 11/4/2014    1 comment / Last Comment: 11/16/2014
    In this rapidly evolving treatment environment, the best available regimen may not yet have been incorporated into the expert guidance.
  • My Take on the Guidance From AASLD/IDSA for Managing Treatment-Experienced Patients With Genotype 3 HCV Infection and Cirrhosis

    Ira M. Jacobson MD - 11/5/2014    2 comments / Last Comment: 11/20/2014
    When treatment-experienced patients with genotype 3 HCV infection and evidence of advanced liver disease seek care, it’s important to treat them now, even if evidence defining the best regimen is limited.
  • My Take on the Guidance From AASLD/IDSA for Treating Patients With Genotype 2 HCV Infection

    Norah Terrault MD, MPH - 11/4/2014    
    The AASLD/IDSA HCV guidance is straight forward regarding treatment-naive patients with genotype 2 HCV infection, but there are a few considerations to keep in mind.